Reports

Drug name	NICE TAs	Comments
Etanercept	TA103 - Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept syringe	TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Etelcalcetide	TA448 - Etelcalcetide for treating secondary hyperparathyroidism
Etranacogene dezaparvovec (Hemgenix®)	Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [TA989]
Everolimus (Afinitor®)	TA432 - Everolimus for advanced renal cell carcinoma after previous treatment TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease TA421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy	Negative outcome - CDF funded for renal, NET, breast. For hospital use only.
Evolocumab	TA394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia & Homozygous familial hypercholesterola EMIA in line with NHS England SSC 1649	To be used in line with NICE TA
Exemestane tablets	TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Exenatide prolonged release injection (Bydureon®)	NICE NG28: Type 2 diabetes in adults - management
Ezetimibe tablets	TA132 - Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
Febuxostat tablets	TA164 - Febuxostat for the management of hyperuricaemia in people with gout

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports